Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-21

Clinical Trial Update: Long Term Safety Study of Tanezumab in Chronic Low Back Pain [Phase 2]

View source ↗

Summary

Phase 2 long-term safety study of tanezumab in chronic low back pain has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Low Back Pain | Phase 2 | Status: TERMINATED | Results posted: 2021-04-21